Increased thrombin-antithrombin III complex during an episode of paroxysmal atrial fibrillation
Kanji Iga MD, Chisato Izumi MD, Moriaki Inoko MD, Shouji Kitaguchi MD, Y
Abstract
Thrombin-antithrombin III complex (TAT) is a marker of thrombin generation
indicating increased coagulability. To investigate whether paroxysmal atrial
fibrillation (PAf) is associated with increased coagulation system, we measured
TAT within 24 hours after the documentation of PAf in 50 patients with structurally
normal heart. Mean age of the study population was 62 years old. In 32 patients,
PAf was documented during routine physical examinations, electrocardiograms
or echocardiograms and in the remaining 18 patients it was reproducibly
documented on more than two Holter electrocardiograms. Group I consisted
of 38 TAT sets data from 38 patients who did not receive anticoagulant therapy
during PAf episodes. At least one week after starting anticoagulant therapy,
TAT was measured again in 10 patients in whom there was evidence of PAf
on the day of measurement. In the remaining 12 patients, PAf occurred while
the patients were receiving anticoagulation. Group II consisted of 22 TAT
data sets from 22 patients who received anticoagulation during PAf episodes.
Average TAT was 5.8ng/ml in group I, while 2.8ng/ml in group II (P<0.0001).
TAT was greater than 5ng/ml in 15 of the 38 patients in group I, and in
4 of the 22 patients in group II. In 20 symptomatic patients, we measured
TAT again when the patients maintained sinus rhythm under the same anticoagulant
therapy; 4 patients were receiving and 16 patients were not receiving anticoagulation.
TAT decreased from 6.4ng/ml to 2.3ng/ml on average when PAf disappeared
and sinus rhythm was maintained (P=0.0009). Coagulation system increases
transiently during or shortly after PAf episodes in about 40 % of PAf patients
. As patients with prior anticoagulation had a relatively low TAT value,
anticoagulant therapy might be useful in patients with PAf.